Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicament composition for treating cardiac and cerebral vascular disease

A technology for cardiovascular and cerebrovascular diseases and compositions, which can be used in cardiovascular system diseases, drug combinations, pharmaceutical formulations, etc., and can solve the problems of large and unsafe drug use.

Inactive Publication Date: 2012-06-27
GUIZHOU XINBANG PHARMACEUTICAL CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The purpose of the present invention is to combine two drugs that act on different targets and can significantly reduce the infarct area of ​​the brain tissue and significantly reduce the behavioral disorder caused by brain tissue necrosis. Since the drug interaction is a synergistic interaction, And it is stronger than the additive effect of individual drugs; it solves the problem of unsafe drug dosage; it makes the drug curative effect faster and stronger
The purpose of the present invention is to address the above-mentioned deficiencies in the prior art, and to provide a kind of pharmaceutical composition for the treatment of ischemic cerebrovascular disease, mainly in order to solve the problem of using ginsenoside or safflower yellow alone as a method for treating ischemic cerebrovascular disease. Various problems in vascular diseases, specific receptors manipulate Ca 2+ Combined use of channel blocker ginsenoside Rd and platelet activating factor receptor antagonist safflower yellow

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament composition for treating cardiac and cerebral vascular disease
  • Medicament composition for treating cardiac and cerebral vascular disease
  • Medicament composition for treating cardiac and cerebral vascular disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] The preparation of embodiment 1 injection

[0055] 1. Prescription:

[0056] Ginsenoside-Rd 6g

[0057] Safflower Yellow A 4g

[0058] Sodium chloride 9g

[0059] 1,2-propanediol 100ml

[0060] Water for injection about 900ml

[0061] Makes 1000ml

[0062] 2. Preparation:

[0063] Take ginsenoside-Rd, safflower yellow A, sodium chloride, 1,2-propanediol; dissolve sodium chloride to 500ml of 20% propylene glycol aqueous solution, add ginsenoside-Rd, safflower yellow A, at 60~70℃ Stir on a water bath until fully dissolved, cool to room temperature, add the remaining amount of water for injection to 1000ml, mix well and filter with a 0.22μm filter membrane. The filtrate is filled in separate bottles, sealed, and sterilized to obtain the product.

Embodiment 2

[0064] The preparation of embodiment 2 dropping pills

[0065] 1. Prescription:

[0066] Ginsenoside-Rd 10g

[0067] Safflower Yellow A 20g

[0068] Macrogol 6000 37g

[0069] Makes 1000 capsules

[0070] 2. Preparation:

[0071] Take polyethylene glycol 6000, put it in a container, heat it to 70-80°C, wait until it is completely melted, and when the temperature drops to about 50°C, add ginsenoside-Rd and safflower yellow A to melt, and control the temperature at 40°C -50°C, pour it into a dropping pill machine and drop it into simethicone oil to make a dropping pill.

Embodiment 3

[0072] Example 3 Preparation of Sublingual Tablets

[0073] 1. Prescription:

[0074] Ginsenoside-Rd 20g

[0075] Safflower Yellow A 10g

[0076] Hydroxypropyl methylcellulose (E-50) 80g

[0077] Hydroxypropylmethylcellulose (E-4M) 50g

[0078] Hydroxypropyl Cellulose 20g

[0079] Micronized silica gel 3g

[0080] Magnesium Stearate 7g

[0081] Makes 1000 pieces

[0082] 2. Take ginsenoside-Rd, safflower yellow A, hydroxypropyl methylcellulose (E-50), hydroxypropyl methylcellulose (E-4M), hydroxypropyl cellulose, micropowder silica gel, hard Magnesium fatty acid is mixed evenly by the method of increasing in equal amounts, and directly compressed into sublingual lozenges, to obtain.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicine and discloses a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases. The pharmaceutical composition is prepared by ginsenoside and carithamine as main ingredients and can be prepared into pharmaceutically or clinically acceptable dosage forms. The pharmaceutical composition has functions of expanding blood vessels of brain, reducing cerebral vascular resistance, increasing cerebral blood flow, obviously minimizing infarct area of brain tissues, obviously lightening behavior disorders caused by brain tissue necrosis, and the like, and can be used for preparing medicaments for treating diseases such as cerebral circulation insufficiency, cerebral thrombosis, cerebral embolism, brain blood vessels spasm,brain insufficiency, senile dementia, Parkinsonism, cerebral apoplexy, hypertension, hyperlipemia, arteriosclerosis, coronary heart disease, angina pectoris, miocardial infarction, etc.

Description

Technical field: [0001] The invention relates to a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, which is made of ginsenoside and safflower yellow and belongs to the technical field of medicines. Background technique: [0002] Cerebral thrombosis, cerebral arteriosclerosis, coronary heart disease, angina pectoris and other cardiovascular and cerebrovascular diseases seriously threaten human life and health. According to epidemiological investigations, the incidence and death of cardiovascular and cerebrovascular diseases have The incidence rate of cardiovascular and cerebrovascular diseases in the world is 1.4-200 / 100,000 population, and the average death rate is 100 / 100,000 population. The mortality rate of cardiovascular and cerebrovascular diseases in my country has leapt to the top top of the list of diseases. Therefore, it is very necessary to carry out research on therapeutic drugs, and it is also a hot spot of research at home and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/704A61K31/351A61P9/10A61P9/08A61P9/00
Inventor 张观福杜健
Owner GUIZHOU XINBANG PHARMACEUTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com